Earnings ·
Aligos Therapeutics reported second quarter 2026 results and recent business progress
ALGSAligos Therapeutics, Inc.
Aligos Therapeutics reported second quarter 2026 results and recent business progress. The company received a $25 million upfront payment from Xiamen Amoytop Biotech for the exclusive Greater China license of pevifoscorvir sodium, plus a $3 million milestone triggered by IND approval for its ASO candidate ALG-170675 in China. Pevifoscorvir sodium completed enrollment in the Phase 2 B-SUPREME study and received Breakthrough Therapy Designation from China's NMPA. Aligos reported a net loss of $1.5 million, or $(0.14) per share, compared to a $15.9 million loss in the prior year period. Cash, cash equivalents, and investments totaled $30.4 million as of June 30, 2026, excluding the July upfront payment. The company stated its cash position provides sufficient funding through the fourth quarter of 2026. Aligos Therapeutics is a clinical-stage biotechnology company developing therapies for liver and viral diseases.